Haemalogix

Developer of immunotherapies for blood cancers and autoimmune diseases

placeSydney, New South Wales, Australia calendar_todayFounded 2014 groups8 employees language haemalogix.com

Innovation

12 patent families (5 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 326 times.

YearFilings
20151
20162
20171
20181
20193
20204
20215
20224
20233
20244
20255
20262

Social engagement

Social engagement: 1.1K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

3 investors on record; lead investors include Platinum.

Investor typeCountShare
Accelerator & incubator133%
Bank & private debt133%
Other / undisclosed133%

Recent activity

18 May 2026
Milestone
regulatory
27 Mar 2026
Event
Impact Investment Summit Asia Pacific
23 Mar 2026
Event
Impact Investment Summit Asia Pacific
Coming soon